Innovative New Cell and Gene Therapies Show Transformative Benefits
August 18, 2022
Prasad, Raju
Slowing of Clinic Trial Data Hampers Early-Stage Biotechs
March 18, 2022
Nierengarten, David
Low Cost of Capital Sets Stage for Uptick in Biotech M&A
March 18, 2021
Nierengarten, David
M&A Starting to Pick Up as Valuations Come Down
October 04, 2019
Yang, Difei
A Big Year Ahead for Gene and Cell Therapy Companies
March 22, 2019
Prasad, Raju
Major Pharmas Becoming Increasingly Comfortable with Gene Therapy
March 22, 2019
Zhong, Yun
The First Half of 2019 Expected to Be Rough for the Biotech Sector
March 15, 2019
Singh, Hartaj
CRISPR and NASH Will Be Particularly Interesting and Exciting in 2019
March 15, 2019
Seedhouse, Steven
Relatively Healthy Valuations for Development-Stage Companies
October 02, 2018
Nierengarten, David
Data Consistency is Important When Investing in Gene Therapy
March 21, 2018
Chattopadhyay, Debjit
Gene Editing Companies Have Long-Term Potential to Be M&A Targets
March 16, 2018
Amusa, Gbola
Downturn in Biotech Creates Opportunities for Investors to Realize Superior Gains
April 21, 2017
Markey, Keith A.
Biotech Space on the Cusp of Seismic Changes
April 21, 2017
Chattopadhyay, Debjit
Applying Bottom-Up Fundamental Research in the Large-Cap Space
February 24, 2017
Fitzpatrick, Owen
Opportunities in Regenerative Medicine, Cancer Immunotherapy Markets for Value Investors
July 06, 2015
Biotech Space Concentrates on Gene Therapy, CAR T-Cell Technology Side
July 23, 2014
Targeted Genetic and Cell Therapies Stand Out in Biotechnology
April 01, 2014
Lon L.e. Vining - Angoss Software Corporation (anc:tsx.v)
June 04, 2007
Todd Ahlsten - Parnassus Investments
February 17, 2003
